

Clovis Oncology Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 08-Oct-2012

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

[Return to Table of Contents](#)

Clovis Oncology Inc

COMPANY OVERVIEW

Company Name	Clovis Oncology Inc
Parent Company Name	Clovis Oncology Inc
Website	http://www.clovisoncology.com/
Country	US
Number of Drugs in Active Development	5
Number of Inactive Drugs	1
Number of Patents as Owner	4
Number of Patents as Third Party	1
Number of Deals	7
Key Indications	Non-small-cell lung cancer,Breast tumor,Ovary tumor,Pancreas tumor,Melanoma,Gastrointestinal stromal tumor,Solid tumor,Cancer,Metastasis,Prostate tumor
Key Target-based Actions	KIT gene inhibitor,Equilibrative nucleoside transporter 1 modulator,VEGF ligand inhibitor
Key Technologies	Oral formulation,Small molecule therapeutic,Drug combination,Formulation preservation,Monoclonal antibody humanized,Parenteral formulation

COMPANY PROFILE

SUMMARY

Clovis Oncology, founded in May 2009 by former Pharmion executives, in-licenses cancer drugs at all stages of clinical development.

LOCATION

Clovis is headquartered in Boulder, CO, and has additional offices in San Francisco, CA and Cambridge, UK.

FINANCIAL

In March 2012, Clovis filed a registration statement on Form S-1 with the US SEC for an underwritten public offering of its \$75 million common stock shares. Underwriters were to be granted an option to purchase up to \$11.25 million of additional shares to cover over-allotments; in April 2012, the company offered the underwritten public offering of 3.75 million shares priced at \$20 per share and additional 562,500 shares were granted to the underwriters. The offering was expected to close on April 10, 2012.

In November 2011, the company priced its initial public offering of 10 million shares of its common stock at \$13 per share. At that time, the company also granted the underwriters a 30-day over-allotment option to buy an additional 1.5 million shares of its common stock. Clovis's shares would trade on the NASDAQ Global Select Market under the ticker symbol 'CLVS' from November 16, 2011, and the offering was expected to close on November 21, 2011. Later in November 2011, underwriters exercised their over-allotment option to purchase an additional 0.7 million shares.

In May 2009, Clovis raised \$145 million in start-up financing

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	5	1	6
Gastrointestinal disease	2	1	3
Gynecology and obstetrics	2	0	2
Genitourinary disease	2	0	2
Respiratory disease	2	0	2
Endocrine disease	2	0	2
Dermatological disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	4
Discovery	1
Discontinued	1

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Discovery/Design	1	0	0	0	1
Technology - Other Proprietary	0	0	3	0	3
Drug - Development/Commercialization License	0	0	3	0	3

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	4	8
Gastrointestinal disease	1	3
Respiratory disease	2	2
Gynecology and obstetrics	0	1
Genitourinary disease	0	1
Endocrine disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	1	3
Phase 1	3	4
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Immune disorder	2	0	2
Neoplasm	4	1	5

[Return to Table of Contents](#)



Metabolic disorder	1	0	1
Neurological disease	1	0	1
Andrology	2	0	2
Cardiovascular disease	1	0	1
Endocrine disease	2	1	3
Genitourinary disease	2	0	2
Dermatological disease	2	0	2
Gastrointestinal disease	3	0	3
Hematological disease	2	0	2
Respiratory disease	2	0	2
Injury	1	0	1
Gynecology and obstetrics	1	1	2

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology SNAPSHOT

Drug Name	gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology
Key Synonyms	gemcitabine elaidate
Originator Company	Clavis Pharma ASA
Active Companies	Clovis Oncology Inc
Inactive Companies	Clavis Pharma ASA
Highest Status	Phase 2 Clinical
Active Indications	Pancreas tumor;Non-small-cell lung cancer
Target-based Actions	
Other Actions	Anticancer antimetabolite;DNA synthesis inhibitor
Technologies	Prodrug;Lipid;Small molecule therapeutic;Intravenous formulation
Last Change Date	24-Aug-2012

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology DEVELOPMENT PROFILE

SUMMARY

Clovis Oncology, under license from Clavis Pharma, is developing an iv formulation of gemcitabine elaidate (CO-101, CO-1.01; formerly CP-4126), an elaidic fatty acid-derived prodrug of gemcitabine, developed using Clavis's lipid vector technology (LVT), for the potential treatment of cancer, including solid tumors such as pancreatic cancer and NSCLC . In April 2009, a phase II trial for pancreatic cancer was initiated ; in October 2011, the study was completed ; in December 2011, data were expected in the fourth quarter of 2012. In July 2012, a phase I trial for NSCLC was initiated and expected to complete in March 2013. In March 2012, Clovis planned to file for approval in the US and EU by the mid 2013 .

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Pancreas tumor	Australia	Phase 2 Clinical	11-Nov-2010
Clovis Oncology Inc	Pancreas tumor	Europe	Phase 2 Clinical	24-Nov-2009
Clovis Oncology Inc	Pancreas tumor	South America	Phase 2 Clinical	11-Nov-2010
Clovis Oncology Inc	Pancreas tumor	US	Phase 2 Clinical	24-Nov-2009

[Return to Table of Contents](#)




Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Non-small-cell lung cancer	UK	Phase 1 Clinical	09-Aug-2012
Clovis Oncology Inc	Non-small-cell lung cancer	US	Phase 1 Clinical	16-Jul-2012
Clavis Pharma ASA	Pancreas tumor	Australia	Discontinued	11-Nov-2010
Clavis Pharma ASA	Pancreas tumor	Europe	Discontinued	24-Nov-2009
Clavis Pharma ASA	Pancreas tumor	South America	Discontinued	11-Nov-2010

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology DEVELOPMENT STATUS

HISTORICAL DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Clavis Pharma ASA	Pancreas tumor	Europe	Phase 2 Clinical	16-Apr-2009
Clavis Pharma ASA	Pancreas tumor	South America	Phase 2 Clinical	21-Oct-2010
Clavis Pharma ASA	Solid tumor	Europe	Phase 1 Clinical	18-Sep-2006
Clavis Pharma ASA	Cancer	Norway	Discovery	17-Apr-2005

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
210829-30-4	2
	
Name	Type
gemcitabine elaidate	INN; USAN
CP-4126	Research Code
CO-101	Research Code
CO-1.01	Research Code

[Return to Table of Contents](#)

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology DRUG NAMES

Names	Type
CP-4126	Research Code
fatty acid gemcitabine prodrug (iv, lipid vector technology, cancer), Clavis	
CP-4126 (iv, lipid vector technology, cancer), Clavis Pharma	
gemcitabine elaidate	INN, USAN
CP-4126 (intravenous, lipid vector technology, cancer), Clavis Pharma/Clovis Oncology	
CO-101	Research Code
CO-1.01	Research Code
gemcitabine elaidate (intravenous, lipid vector technology), Clavis Pharma/Clovis Oncology	
CO-101 (intravenous, lipid vector technology), Clavis Pharma/Clovis Oncology	
gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology	

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Pancreas tumor											
0	0	0	0	0	2	0	0	0	1	0	3
Metastatic pancreas cancer											
0	0	0	0	1	2	0	0	0	0	1	2
Solid tumor											
0	0	0	0	0	0	0	2	0	0	0	2
Non-small-cell lung cancer											
0	0	0	0	0	0	1	1	0	0	1	1
Advanced solid tumor											
0	0	0	0	0	0	1	1	0	0	1	1

[Return to Table of Contents](#)

Adenocarcinoma											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	4	1	3	0	1	2	8


Phase Definitions

- Phase 3 Clinical**
 Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)
- Phase 2 Clinical**
 Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)
- Phase 1 Clinical**
 Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

gemcitabine elaidate (iv lipid vector, cancer), Clovis Oncology DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Clavis Pharma ASA	4	0	2	0	6
Roche Holding AG	1	0	1	0	2
Clovis Oncology Inc	0	0	2	0	2
US Government	1	0	0	0	1
Innovation Norway	0	0	1	0	1
Oslo University Hospital	0	0	1	0	1
Norsk Hydro AS	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart


Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	2	0	2
Drug - Development/Commercialization License	1	0	1
Drug - Funding	1	0	1
Patent - Exclusive Rights	1	0	1
Drug - Screening/Evaluation	1	0	1
Drug - Development Services	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Clavis Pharma ASA	4	0	4
Clovis Oncology Inc	3	0	3
Roche Holding AG	2	0	2
Norsk Hydro AS	1	0	1
University of Alberta	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	2
General interest	1
New use	1

[Return to Table of Contents](#)

rucaparib phosphate (iv, solid tumors), Clovis

rucaparib phosphate (iv, solid tumors), Clovis SNAPSHOT

Drug Name	rucaparib phosphate (iv, solid tumors), Clovis
Key Synonyms	rucaparib;rucaparib phosphate
Originator Company	The University of Newcastle Upon Tyne
Active Companies	Clovis Oncology Inc
Inactive Companies	Pfizer Inc;The University of Newcastle Upon Tyne;Cancer Research Campaign Technology Ltd;Agouron Pharmaceuticals Inc
Highest Status	Phase 2 Clinical
Active Indications	Breast tumor;Melanoma;Ovary tumor
Target-based Actions	PARP inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic;Intravenous formulation
Last Change Date	18-Sep-2012

rucaparib phosphate (iv, solid tumors), Clovis DEVELOPMENT PROFILE

SUMMARY

Clovis Oncology, under license from Pfizer (originally licensed from the University of Newcastle Upon Tyne and Cancer Research Campaign Technology (CRCT)), is developing an iv formulation of rucaparib phosphate (PF-1367338, PF-01367338, AG-014699; CO-338; structure shown), the lead in a series of oral and iv inhibitors of poly(ADP-ribose) polymerase (PARP), for the potential treatment of cancer including melanoma, breast cancer and ovarian cancer ,,. In March 2005, phase II studies of rucaparib phosphate in melanoma began. In December 2007, a phase II trial for hereditary breast or ovarian cancer began. By November 2006, a phase III trial was planned in melanoma .

Pfizer was previously investigating the drug for diabetic macular edema. In April 2007, the company planned a phase II trial in subjects with diabetic macular edema, however in May 2007, the trial was withdrawn prior to enrollment ; since that time, no further development for this indication has been reported.

Clovis Oncology is also developing an oral formulation of rucaparib phosphate.

KuDOS Pharmaceuticals has also investigated PARP inhibitors stemming from CRCT and University of Newcastle research.

rucaparib phosphate (iv, solid tumors), Clovis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)


Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Breast tumor	UK	Phase 2 Clinical	02-Jun-2011
Clovis Oncology Inc	Melanoma	Western Europe	Phase 2 Clinical	02-Jun-2011
Clovis Oncology Inc	Ovary tumor	UK	Phase 2 Clinical	02-Jun-2011
Cancer Research Campaign Technology Ltd	Cancer	Western Europe	Discontinued	02-Oct-1997
Pfizer Inc	Breast tumor	UK	Discontinued	02-Jun-2011
Pfizer Inc	Melanoma	Western Europe	Discontinued	02-Jun-2011
Pfizer Inc	Ovary tumor	UK	Discontinued	02-Jun-2011
The University of Newcastle Upon Tyne	Cancer	Western Europe	Discontinued	02-Oct-1997
Pfizer Inc	Diabetic macular edema	US	No Development Reported	24-Nov-2008

rucaparib phosphate (iv, solid tumors), Clovis DEVELOPMENT STATUS

HISTORICAL DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfizer Inc	Breast tumor	UK	Phase 2 Clinical	31-Dec-2007
Pfizer Inc	Melanoma	Western Europe	Phase 2 Clinical	31-Mar-2005
Pfizer Inc	Ovary tumor	UK	Phase 2 Clinical	31-Dec-2007
Pfizer Inc	Breast tumor	Western Europe	Clinical	24-Nov-2006
Agouron Pharmaceuticals Inc	Cancer	Western Europe	Discovery	02-Oct-1996
Pfizer Inc	Diabetic macular edema	US	Discovery	04-Apr-2007
Pfizer Inc	Melanoma	Western Europe	Discovery	19-Jun-2000


rucaparib phosphate (iv, solid tumors), Clovis CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
459868-92-9	2
	

[Return to Table of Contents](#)


Name	Type
rucaparib phosphate	USAN
AG-014699	Research Code
AG-14699	Research Code
PF-01367338	Research Code
PF-1367338	Research Code

CAS Registry Number:	Confidence Level:
283173-50-2	2



Name	Type
rucaparib	INN; USAN
AG-14447	Research Code
AG-014447	Research Code

CAS Registry Number:	Confidence Level:
	3



Name	Type
AG-14361	Research Code

[Return to Table of Contents](#)

rucaparib phosphate (iv, solid tumors), Clovis DRUG NAMES

Names	Type
TBI-361	Research Code
AG-14073	Research Code, Analogue
AG-14167	Research Code, Analogue
AG-14361	Research Code
poly ADP-ribose polymerase inhibitors, Agouron	
cancer therapeutics, Agouron	
AG-014699	Research Code
PARP inhibitors (melanoma), Pfizer	
poly-ADP-ribose polymerase inhibitors (melanoma, breast/ ovarian cancer), Pfizer	
AG-14447	Research Code
AG-14699	Research Code
AG-014447	Research Code
PF-01367338	Research Code
NU-1098	Research Code
PF-1367338	Research Code
rucaparib phosphate	USAN
rucaparib	INN, USAN
poly-ADP-ribose polymerase inhibitors (melanoma, breast/ ovarian cancer), Clovis	
CO-338	Research Code
rucaparib phosphate (iv, solid tumors), Clovis	

rucaparib phosphate (iv, solid tumors), Clovis CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All

[Return to Table of Contents](#)

Solid tumor											
0	0	0	0	0	1	1	2	0	0	1	3
Breast tumor											
0	0	0	0	1	2	0	0	0	0	1	2
Ovary tumor											
0	0	0	0	0	2	0	0	0	0	0	2
Diabetes mellitus											
0	0	0	0	0	1	0	0	0	0	0	1
Melanoma											
0	0	0	0	0	1	0	0	0	0	0	1
Diabetic retinopathy											
0	0	0	0	0	1	0	0	0	0	0	1
Metastatic breast cancer											
0	0	0	0	0	1	0	0	0	0	0	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	1	5	1	2	0	0	2	7

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

rucaparib phosphate (iv, solid tumors), Clovis DEALS AND PATENTS

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Pfizer Inc	1	0	2	0	3
MDxHealth SA	3	0	0	0	3
University of Newcastle	2	0	0	0	2
Cancer Research UK	0	0	2	0	2
Clovis Oncology Inc	0	0	2	0	2
The University of Newcastle Upon Tyne	0	0	1	0	1
Foundation Medicine Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development Services	3	0	3
Drug - Early Research/Development	2	0	2
Technology - Other Proprietary	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Pfizer Inc	6	0	6
Cancer Research UK	3	0	3
Clovis Oncology Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
General interest	2
Product (derivative)	1
Product	1
Component of Combination	1
New use	1

[Return to Table of Contents](#)

CO-1686

CO-1686 SNAPSHOT

Drug Name	CO-1686
Key Synonyms	
Originator Company	Avila Therapeutics Inc
Active Companies	Celgene Corp;Clovis Oncology Inc
Inactive Companies	Avila Therapeutics Inc
Highest Status	Phase 2 Clinical
Active Indications	Non-small-cell lung cancer
Target-based Actions	EGFR family tyrosine kinase receptor inhibitor
Other Actions	Anticancer protein kinase inhibitor;Apoptosis stimulator
Technologies	Small molecule therapeutic;Oral formulation
Last Change Date	09-Aug-2012

CO-1686 DEVELOPMENT PROFILE

SUMMARY

Clovis Oncology and Celgene (following its acquisition of Avila Therapeutics) are developing CO-1686 (AVL-301), the lead from a program of oral, small-molecule EGFR mutant-selective inhibitors (EMSI), created using Avila's Avilomics technology, that target T790M EGFR-mutants, as well as initial-activating-EGFR mutations (including L858R and exon 19 deletions), for the potential treatment of NSCLC,. In March 2012, a US phase I/II trial began. In January 2012, phase I studies in Europe and Asia were planned to begin later that year ; later in January 2012, the FDA approved an IND filing.

CO-1686 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Non-small-cell lung cancer	Europe	Phase 2 Clinical	20-Mar-2012
Clovis Oncology Inc	Non-small-cell lung cancer	US	Phase 2 Clinical	20-Mar-2012
Celgene Corp	Non-small-cell lung cancer	US	Discovery	08-Mar-2012

CO-1686 DEVELOPMENT STATUS

HISTORICAL DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
---------	------------	---------	--------------------	------

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Avila Therapeutics Inc	Non-small-cell lung cancer	US	Discovery	25-May-2010
Clovis Oncology Inc	Non-small-cell lung cancer	US	Discovery	25-May-2010

CO-1686 DRUG NAMES

Names	Type
epidermal growth factor receptor mutant-selective inhibitor (oral, T790M mutant-targeting, non-small-cell lung cancer), Avila Therapeutics/Clovis Oncology	
EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Avila Therapeutics/Clovis Oncology	
EMSI (oral, T790M mutant-targeting, NSCLC), Avila Therapeutics/Clovis Oncology	
CNX-419	Research Code
CO-1686	Research Code
AVL-301	Research Code
EGFR mutant-selective inhibitor (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology	
EMSI (oral, T790M mutant-targeting, NSCLC), Celgene/Clovis Oncology	
790M mutant-targeting, non-small-cell lung cancer), Celgene/Clovis Oncology	

CO-1686 CLINICAL TRIALS

Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Non-small-cell lung cancer											
0	0	0	0	0	0	1	1	0	0	1	1

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	1	0	0	1	1

[Return to Table of Contents](#)

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

CO-1686 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Clovis Oncology Inc	0	0	2	0	2
Celgene Corp	1	0	0	0	1
Roche Holding AG	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Celgene Corp	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

[Return to Table of Contents](#)

rucaparib phosphate (oral, solid tumors), Clovis

rucaparib phosphate (oral, solid tumors), Clovis SNAPSHOT

Drug Name	rucaparib phosphate (oral, solid tumors), Clovis
Key Synonyms	rucaparib phosphate
Originator Company	The University of Newcastle Upon Tyne
Active Companies	Clovis Oncology Inc
Inactive Companies	Pfizer Inc;The University of Newcastle Upon Tyne;Agouron Pharmaceuticals Inc;Cancer Research Technology Ltd
Highest Status	Phase 2 Clinical
Active Indications	Breast tumor;Solid tumor;Ovary tumor
Target-based Actions	PARP inhibitor
Other Actions	Anticancer
Technologies	Tablet formulation;Small molecule therapeutic;Oral formulation
Last Change Date	18-Sep-2012

rucaparib phosphate (oral, solid tumors), Clovis DEVELOPMENT PROFILE

SUMMARY

Clovis Oncology, under license from Pfizer (originally licensed from the University of Newcastle Upon Tyne and Cancer Research Campaign Technology (CRCT)), is developing an oral formulation of rucaparib phosphate (PF-1367338, PF-01367338, AG-014699; CO-338), the lead from a program of oral and iv inhibitors of poly(ADP-ribose) polymerase (PARP), for the potential treatment of cancer, including breast cancer, ovarian cancer, and other solid tumors,. In October 2011, dosing in a phase II trial for hereditary breast or ovarian cancer, originally set up for iv dosing, was changed to oral only. In November 2011, a phase I/II trial of the oral formulation in patients with breast cancer and other solid tumors began .

Clovis Oncology is also developing an iv formulation of rucaparib phosphate.

rucaparib phosphate (oral, solid tumors), Clovis DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Breast tumor	UK	Phase 2 Clinical	24-Oct-2011
Clovis Oncology Inc	Breast tumor	US	Phase 2 Clinical	30-Nov-2011
Clovis Oncology Inc	Ovary tumor	UK	Phase 2 Clinical	24-Oct-2011
Clovis Oncology Inc	Solid tumor	UK	Phase 2 Clinical	30-Nov-2011

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Solid tumor	US	Phase 2 Clinical	30-Nov-2011
Cancer Research Technology Ltd	Cancer	UK	Discontinued	02-Oct-1997
Pfizer Inc	Solid tumor	UK	Discontinued	02-Jun-2011
The University of Newcastle Upon Tyne	Cancer	UK	Discontinued	02-Oct-1997


rucaparib phosphate (oral, solid tumors), Clovis DEVELOPMENT STATUS

HISTORICAL DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Solid tumor	UK	Phase 1 Clinical	02-Jun-2011
Pfizer Inc	Solid tumor	UK	Phase 1 Clinical	05-Apr-2010
Agouron Pharmaceuticals Inc	Cancer	US	Discovery	02-Oct-1997

rucaparib phosphate (oral, solid tumors), Clovis CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
459868-92-9	2



Name	Type
rucaparib phosphate	USAN
AG-014699	Research Code
AG-14699	Research Code
PF-01367338	Research Code
PF-1367338	Research Code

[Return to Table of Contents](#)


rucaparib phosphate (oral, solid tumors), Clovis DRUG NAMES

Names	Type
AG-014699	Research Code
AG-14699	Research Code
PF-01367338	Research Code
PF-1367338	Research Code
rucaparib phosphate	USAN
rucaparib phosphate (oral, solid tumors), Clovis	

rucaparib phosphate (oral, solid tumors), Clovis DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Foundation Medicine Inc	1	0	0	0	1
Clovis Oncology Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

PATENTS

Patents by Parent Company Chart

Chart displayed by Owner/Third Party




[Return to Table of Contents](#)

Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Clovis Oncology Inc	1	0	1
Pfizer Inc	1	0	1

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1

KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology

KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology SNAPSHOT

Drug Name	KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology
Key Synonyms	
Originator Company	Clovis Oncology Inc
Active Companies	Clovis Oncology Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Gastrointestinal stromal tumor
Target-based Actions	KIT gene inhibitor
Other Actions	Anticancer
Technologies	Small molecule therapeutic;Oral formulation
Last Change Date	17-Jul-2012

KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology DEVELOPMENT PROFILE

SUMMARY

Clovis Oncology is investigating a KIT inhibitor, targeting resistance mutations particularly exon 17, for the potential oral treatment of gastrointestinal stromal tumor (GIST). In July 2012, the company planned to file an IND within three years, if the program was successful.

KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Clovis Oncology Inc	Gastrointestinal stromal tumor	US	Discovery	16-Jul-2012

KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology DRUG NAMES


Names	Type
KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology	

KIT gene inhibitor (oral, gastrointestinal stromal tumor), Clovis Oncology DEALS AND PATENTS

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Clovis Oncology Inc	1	0	0	0	1
Array BioPharma Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Discovery/Design	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

